Given the presence of a targetable gene fusion, the presence of residual tumor, and the morbidity associated with additional surgery or radiation, the patient was subsequently treated with the MET inhibitor cabozantinib and demonstrated a complete pathological response (Fig. 3D). Here, MET is linked to neoplasm.